Dermatological Drugs - Uganda

Uganda

In Uganda, the revenue in the Dermatological Drugs market is forecasted to reach US$4.97m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 5.61%, leading to a market volume of US$6.53m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$11,670.00m in 2024.
The demand for dermatological drugs in Uganda is steadily increasing due to rising awareness about skin health and access to healthcare facilities.

Key regions: United Kingdom, Canada, Japan, Europe, China

Market

Region

Region comparison

Currency

Analyst Opinion

The Dermatological Drugs market in Uganda has been steadily growing in recent years, driven by several factors.

Customer preferences: Uganda has a high prevalence of skin diseases, including fungal infections, eczema, and psoriasis. As a result, there is a high demand for dermatological drugs in the country. Customers in Uganda prefer affordable and effective drugs that can treat a wide range of skin conditions.

Trends in the market: One of the major trends in the Dermatological Drugs market in Uganda is the increasing availability of generic drugs. Generic drugs are cheaper than branded drugs and are becoming more popular among customers who cannot afford expensive treatments. Another trend is the rising awareness of dermatological health among the population, which has led to an increase in the number of people seeking treatment for skin conditions.

Local special circumstances: The availability of dermatologists and skin care specialists in Uganda is limited, particularly in rural areas. This has led to a demand for over-the-counter (OTC) drugs that can be easily obtained and self-administered. Additionally, the hot and humid climate in Uganda makes the population more susceptible to skin infections and diseases, leading to a higher demand for dermatological drugs.

Underlying macroeconomic factors: The healthcare sector in Uganda has been growing in recent years, with increased government investment in healthcare infrastructure and services. This has led to an increase in the availability of healthcare services, including dermatological treatments. The growing middle class in Uganda has also contributed to the growth of the Dermatological Drugs market, as more people can afford to pay for healthcare services and drugs. However, the market is still largely dominated by multinational pharmaceutical companies, with few local players in the industry.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.